Condiciones de salud que Terminalia puede ayudar a apoyar.
Terminalia arjuna bark has been evaluated in multiple clinical trials for chronic stable angina. A landmark double-blind, placebo-controlled crossover RCT (n=58 males, NYHA class II–III) found arjuna reduced angina frequency and need for rescue nitrates comparably to isosorbide mononitrate. A systematic review and meta-analysis confirmed these findings across several trials, though methodological quality was variable.
Both T. chebula and T. arjuna have demonstrated substantial antioxidant activity in multiple in vitro, animal, and human studies. T. chebula is rich in gallic acid, ellagic acid, chebulagic acid, corilagin, and quercetin, which show potent free radical scavenging. A randomized controlled trial found T. arjuna's antioxidant effects comparable to vitamin E in coronary heart disease patients.
T. arjuna has documented anti-atherogenic and coronary vasodilatory activity supported by clinical and pre-clinical studies. Clinical studies report improved endothelial function in coronary artery disease patients. T. chebula has also demonstrated anti-hypercholesterolaemic and anti-atherogenic activity in animal models.
T. chebula has documented anti-arthritic activity in both pre-clinical and clinical settings. A randomized, double-blind, placebo-controlled trial found T. chebula extract (AyuFlex) at 250 mg and 500 mg twice daily significantly reduced pain and joint discomfort versus placebo. The fruit has been used in traditional Asian medicine for arthritic diseases for over a thousand years.
T. arjuna bark demonstrates clinically documented hypotensive activity. A randomized, double-blind, placebo-controlled trial in hypertensive geriatric patients found 1,000 mg/day for 12 weeks significantly reduced both systolic and diastolic blood pressure alongside improved antioxidant status. Pre-clinical studies confirm coronary vasodilatory and inotropic mechanisms.
T. chebula has documented antidiabetic activity in animal models and limited human trials. A prospective randomized double-blind placebo-controlled study (n=60 type 2 diabetic patients) evaluated aqueous T. chebula extract at 250 mg and 500 mg twice daily for 12 weeks, assessing endothelial function and oxidative stress biomarkers. A combination formula clinical trial also demonstrated reduced fasting blood glucose in hyperlipidemic type 2 diabetic women.
T. chebula methanol extracts have demonstrated antifungal activity against Candida albicans (including clotrimazole-resistant strains) in vitro. T. catappa extracts were tested against Candida biofilms on denture materials in a laboratory study. Traditional use against oral candidiasis is documented. Activity is attributed to hydrolyzable tannins and gallic acid.
Terminalia arjuna and T. chebula both show clinically documented lipid-lowering activity. A randomized controlled trial in 105 coronary heart disease patients found T. arjuna bark significantly reduced total and LDL cholesterol with antioxidant effects comparable to vitamin E. A clinical trial in dyslipidemic patients with T. chebula also showed significant decreases in total and LDL cholesterol.
Terminalia species show documented anti-inflammatory activity in both pre-clinical models and human studies. T. chebula extracts inhibit pro-inflammatory cytokines (IL-6, IL-8, TNF-α, IL-1β) and COX-2/PGE2 pathways. A clinical adjuvant therapy study in stable coronary artery disease patients showed T. arjuna significantly attenuated ongoing inflammation and immune imbalance.
T. arjuna bark demonstrates clinically documented positive inotropic activity, coronary vasodilatory effects, and mild antithrombotic/antiplatelet properties that collectively support circulatory function. Animal studies show increased coronary artery flow. A clinical study found reduced platelet count and improved blood pressure in coronary artery disease patients.
T. chebula is used in Ayurveda as a Rasayana for brain health and longevity. A proof-of-concept RCT demonstrated cognitive improvements in aging adults with memory complaints. Preclinical evidence supports neuroprotective mechanisms including BDNF upregulation, antioxidant protection of neural tissue, and anti-neuroinflammatory effects.
T. chebula is documented as a gentle purgative and laxative in Ayurvedic pharmacopoeia, and a clinical trial confirmed bowel-evacuating effects in constipated patients. Unripe fruits are more purgative while ripe fruits are more astringent. It acts as the main purgative ingredient in Triphala.
T. chebula and T. bellirica were evaluated in a randomized, double-blind, placebo-controlled trial in hyperuricemic patients for reduction of serum uric acid levels. Both extracts showed xanthine oxidase inhibitory activity comparable to allopurinol in vitro at relevant concentrations. Traditional use for gout and joint pain is also well-documented.
T. chebula has demonstrated antimicrobial activity against key oral pathogens including Streptococcus mutans, Porphyromonas gingivalis, and Aggregatibacter actinomycetemcomitans in vitro and in a randomized crossover trial. Its decoction is traditionally used as a gargle for gum bleeding and oral ulcers. Triphala mouthwash (containing T. chebula) has been tested in clinical periodontal trials.
T. chebula is documented as possessing anti-aging properties across multiple systems including antioxidant defense, skin aging, cognitive function, and metabolic health. The Heliyon comprehensive review lists 'anti-ageing' activity among its pharmacological properties. A clinical skin aging study and a cognition pilot RCT provide human evidence.
Multiple clinical studies and reviews support Terminalia arjuna bark's cardioprotective role across heart failure, coronary artery disease, and ischemic cardiomyopathy. A double-blind RCT in refractory heart failure patients found clinically meaningful improvement in cardiac performance. Reviews consistently identify anti-ischemic, antioxidant, and inotropic mechanisms.
T. chebula has documented hepatoprotective activity supported by animal studies and traditional pharmacopoeia use. It reduces serum liver enzymes (AST, ALT, LDH) and attenuates hepatic oxidative stress and inflammatory cytokines in experimental liver injury models. Traditionally, T. chebula is listed in the Ayurvedic Pharmacopoeia as a liver tonic and included in Triphala for liver and kidney support.
A randomized, double-blind, placebo-controlled clinical trial found that a standardized combination of T. chebula and Boswellia serrata (300 mg/day, 120 days) significantly improved memory outcomes — including total learning, delayed recall, and immediate recall — in adults aged 40–65 with subjective memory complaints, alongside improved serum BDNF levels.
T. chebula extracts have been shown in clinical and laboratory studies to modulate the oral microbiome by reducing cariogenic and periodontal pathogens. A clinical study found aqueous T. chebula rinse reduced salivary S. mutans counts and raised salivary pH. Triphala mouthwash (containing T. chebula) produced significant reductions in oral streptococcal counts in human subjects.
Standardized T. chebula fruit extract has been evaluated in an 8-week clinical study in subjects with pollution-induced skin damage. The extract provided longer-lasting ROS neutralization than tocopherol, and the clinical study showed statistically significant improvements in skin texture, hydration, tone, firmness, and radiance versus placebo.
Clinical and animal studies demonstrate Terminalia arjuna and T. chebula reduce serum triglycerides. A clinical study in coronary artery disease patients found T. arjuna produced a 17.9% reduction in serum triglycerides. Animal and in vitro data for T. chebula also show significant triglyceride-lowering activity.
T. chebula has demonstrated antiulcer activity in animal models by inhibiting duodenal ulcer development and exerting a cytoprotective effect on gastric mucosa. Traditional Ayurvedic texts document its use for ulcers, and it is listed for ulcerated oral cavity. Animal experimental evidence supports gastric and duodenal protective effects.
T. chebula extracts have documented antiviral activity against multiple viruses in pre-clinical studies. Chebulagic acid and chebulinic acid show superior direct antiviral activity against HSV-2 compared to acyclovir, preventing virus attachment and cell penetration. Antiviral activity against HSV-1, influenza, HIV, and SARS-CoV-2 proteins has been demonstrated in laboratory and computational studies.
T. chebula demonstrates documented wound healing activity in both animal studies and traditional pharmacopoeia. Its paste applied to wounds is described in Ayurvedic texts as anti-inflammatory, analgesic, and healing. Animal studies confirm accelerated cutaneous wound healing, attributed to astringent tannins and antioxidant polyphenols.
T. chebula is well-documented in Ayurvedic and Unani medicine for abdominal discomfort, flatulence, colic pain, and digestive disorders. It is classified as a stomachic, carminative, and gastrointestinal prokinetic agent. Traditional indications are consistent across multiple indigenous medicine systems and pharmacopoeial monographs.
T. chebula (haritaki) has extensive, well-documented traditional use for diarrhea and dysentery across Ayurvedic, Unani, Siddha, and Traditional Chinese Medicine systems. Ripe fruits are used as astringents to control loose stools. Pharmacological data support antidiarrheal mechanisms through astringent tannins and antimicrobial activity, but robust human RCTs for this specific indication are limited.
T. chebula is documented in the Ayurvedic Pharmacopoeia of India for use in intermittent and chronic fevers. Traditional use for fever management is consistent across Ayurvedic, Unani, and folk medicine systems in South and Southeast Asia. Anti-inflammatory mechanisms provide partial mechanistic rationale.
T. chebula (haritaki) is one of the most consistently cited Ayurvedic remedies for hemorrhoids ('arsha'). Traditional texts and the Ayurvedic Pharmacopoeia of India document its use for bleeding piles. Its astringent tannins are considered to reduce bleeding and shrink hemorrhoidal tissue. No dedicated clinical RCTs were identified.
T. chebula is traditionally used in Ayurvedic medicine for kidney and urinary dysfunction, including renal calculi. It is an ingredient in the classical Triphala formula used for liver and kidney dysfunctions as documented in the Ayurvedic Pharmacopoeia. The bark is traditionally used as a diuretic. Animal studies suggest renoprotective antioxidant activity.
T. chebula decoction used as a gargle for sore throat is among the most consistently documented traditional uses across Ayurvedic, Siddha, Unani, and folk medicine systems. Its astringent, antimicrobial, and anti-inflammatory properties are considered responsible. No dedicated clinical RCTs for isolated sore throat endpoints were identified.
Volver